文献速递肿瘤 PET/CT核素与放射性配体治疗

代谢肿瘤体积与总病灶糖酵解对免疫治疗同步寡转移非小细胞肺癌生存的关联

Association of metabolic tumour volume (MTV) and total lesion glycolysis (TLG) with survival in patients with oligometastatic non-small-cell lung cancer treated with immunotherapy: a multicentre retrospective study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-10-10

该多中心回顾性研究纳入105例接受一线(化疗)免疫治疗的同步寡转移非小细胞肺癌患者,按基线MTV和TLG中位值分组。低MTV组中位PFS显著长于高MTV组(14.73 vs 7.63个月,p=0.028),LRT亦与PFS相关,但MTV和TLG均未影响OS。结论为探索性,需前瞻性验证。

要点

  • 基线低MTV与免疫治疗同步寡转移NSCLC患者更长的PFS相关。
  • MTV和TLG均未显示与总生存期(OS)的显著关联。
  • 局部根治治疗(LRT)与PFS改善相关,结果需前瞻性验证。

核心结论

  • 基线MTV初步与接受免疫治疗的同步寡转移非小细胞肺癌患者的PFS相关,但结果属探索性,需更大规模前瞻性队列验证。

研究设计与样本

  • 多中心回顾性研究,纳入2015至2022年间连续105例经[18F]FDG-PET和脑影像分期的同步寡转移NSCLC患者,均接受一线(化疗)免疫治疗且有基线PET可回顾。

主要发现

  • 低MTV组中位PFS显著长于高MTV组:14.73个月(95%CI 7.06-22.40)对7.63个月(95%CI 5.73-9.52),p=0.028。
  • 局部根治治疗(LRT)与PFS相关:19.04个月(95%CI 8.47-29.60)对7.46个月(95%CI 5.25-9.67),p=0.045。
  • MTV和TLG均未显示对OS的显著影响。
  • 多因素分析中仅PD-L1<50%和软组织转移与更短PFS显著相关。

关键数值与推荐

  • 按MTV和TLG中位值分为高值组与低值组进行比较。
  • 研究终点为PFS和OS,主要终点为总体人群中按MTV和TLG分布(高 vs 低)的生存差异,次要终点为与LRT及系统治疗类型的关系。

临床怎么用

  • 基线MTV可能有助于同步寡转移NSCLC免疫治疗患者的PFS风险分层,但尚不能作为常规决策依据。
  • 局部根治治疗(LRT)与PFS改善相关,支持在系统治疗基础上考虑LRT,但需结合前瞻性证据。

局限性

  • 回顾性设计,结果属探索性,需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Current guidelines recommend adding local radical therapy (LRT) to systemic treatment in synchronous oligometastatic non-small-cell lung cancer (sOM-NSCLC), but survival data on immunotherapy-based regimens are limited. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) are prognostic in NSCLC, with higher values linked to worse outcomes. This study examines their association with survival in sOM-NSCLC patients treated with immunotherapy. METHODS: We conducted a multicenter retrospective study including all consecutive patients with [18F]FDG-PET and brain imaging-staged sOM-NSCLC, between 2015 and 2022, who received first-line (chemo)-immunotherapy and had baseline PET-scan available for review. Subgroups were analyzed based on median MTV and TLG values (high vs. low: H-MTV vs. L-MTV, H-TLG vs. L-TLG). Study endpoints were progression-free survival (PFS) and overall survival (OS), according to MTV and TLG distribution (high vs. low), in the overall population (primary endpoint) and in relation to LRT and systemic treatment type (secondary endpoints). RESULTS: 105 patients were included, 50% were male and 73% had non-squamous histology, median age was 64.9 years. Median PFS was significantly longer for L-MTV vs. H-MTV (14.73 months (95%CI, 7.06-22.40) vs. 7.63 months (95%CI, 5.73-9.52), p = 0.028), but also LRT was associated with PFS (19.04 months (95%CI, 8.47-29.60) versus 7.46 months (95%CI, 5.25-9.67), p = 0.045), while neither MTV nor TLG had impact on OS. In multivariate analysis, only PD-L1 < 50% and soft tissue metastases remained significantly associated with shorter PFS. CONCLUSIONS: Baseline MTV is preliminarily associated with PFS in sOM-NSCLC patients treated with immunotherapy, but results are exploratory and need prospective validation in larger cohorts.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ogliari FR, Jongbloed M, Vaes RDW, et al. Association of metabolic tumour volume (MTV) and total lesion glycolysis (TLG) with survival in patients with oligometastatic non-small-cell lung cancer treated with immunotherapy: a multicentre retrospective study. Eur J Nucl Med Mol Imaging. 2025. PMID: 41071344. doi:10.1007/s00259-025-07557-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。